PGAP3

Across TCGA pan-cancer cohorts, PGAP3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PGAP3 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PGAP3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGAP3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD and LSCC are the cancer types where PGAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.768	0.985	.037	9	view →
LSCC	DFS	Median	III,IV	1.000	0.232	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PGAP3–LUAD (DFS)

Open the LUAD breakdown →